BRAF and glioma: Because p-ERK profiling is not yet a Clinical Laboratory Improvement Amendments–approved (CLIA-approved) biomarker that could be analyzed from commercial datasets, we relied on the published literature indicating that MAPK activation is the oncogenic mechanism for BRAF-driven gliomas (75).